The larger room
SYNCHRONIZE-1 · Online June 7, 2026
Does the result hold in a longer, larger obesity trial?
Subject One enters a hall with hundreds of empty chairs drawn on a chart. He circles one for himself. Doctide removes the circle. “You are our guide, not participant number 726.” He takes a seat beside the source notes instead.
What changes here
A phase 3 trial found greater average weight reduction than placebo in adults without diabetes. [1]
Read the study details & dates
725 adults without diabetes
Weekly subcutaneous survodutide at two trial targets (3.6 and 6.0 mg) was compared with placebo, with lifestyle counselling. Treatment-regimen estimates were −12.2% (95% CI −13.6 to −10.8), −13.0% (−14.4 to −11.6), and −5.4% (−6.9 to −4.0), respectively. This analysis includes early discontinuation and specified treatment changes; it is not an on-treatment-only estimate. [1] [2]
What this does not establish
Trial doses identify research groups, not personal-use instructions. There was no active-drug comparator. This abstract review does not establish comparative cardiovascular benefit or resolve rare long-term harms.
Original sources
Primary NEJM abstract reviewed October 27, 2026. Full paper/supplement not accessible in this review; registry had no posted results.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story